Ovid Therapeutics Inc.: 10-Q filed 2022-11-08

Name: Ovid Therapeutics Inc.: 10-Q filed 2022-11-08
Creator: Ovid Therapeutics Inc.

What Ovid Therapeutics Inc. reported in its quarterly report filed 2022-11-08 (fiscal Q3 2022): 39 published measures, 120 facts as tagged in accession 0001628280-22-028772.

This filing

Form: 10-Q (quarterly report)
Filed: 2022-11-08
Fiscal period: fiscal Q3 2022
Accession: 0001628280-22-028772 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Ovid Therapeutics Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-09-30	165,031,865	USD
At 2021-12-31	194,544,757	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2022-09-30	22,981,132	USD
At 2021-12-31	14,798,321	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-09-30	142,050,733	USD
At 2022-06-30	152,147,496	USD
At 2022-03-31	164,996,271	USD
At 2021-12-31	179,746,436	USD
At 2021-09-30	197,021,761	USD
At 2021-06-30	206,709,513	USD
At 2021-03-31	221,109,940	USD
At 2020-12-31	43,631,656	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2022-09-30	58,257,186	USD
At 2021-12-31	187,797,532	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-11,967,771	USD	92
2022-01-01 to 2022-09-30	-42,664,240	USD	273
2022-04-01 to 2022-06-30	-14,588,414	USD	91
2022-01-01 to 2022-03-31	-16,108,056	USD	90
2021-07-01 to 2021-09-30	-11,384,248	USD	92
2021-01-01 to 2021-09-30	148,834,632	USD	273
2021-04-01 to 2021-06-30	-15,788,427	USD	91
2021-01-01 to 2021-03-31	176,007,307	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-46,051,395	USD	273
2021-01-01 to 2021-09-30	130,610,177	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	1,104,440	USD	273
2021-01-01 to 2021-09-30	22,050	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	224,257	USD	273
2021-01-01 to 2021-09-30	794,902	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-83,713,708	USD	273
2021-01-01 to 2021-09-30	-1,659,442	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-09-30	-214,021,753	USD
At 2021-12-31	-171,357,513	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	70,430,554	shares	92
2022-01-01 to 2022-09-30	70,408,657	shares	273
2021-07-01 to 2021-09-30	67,929,894	shares	92
2021-01-01 to 2021-09-30	67,282,495	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	70,430,554	shares	92
2022-01-01 to 2022-09-30	70,408,657	shares	273
2021-07-01 to 2021-09-30	67,929,894	shares	92
2021-01-01 to 2021-09-30	67,848,033	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-0.17	USD/shares	92
2022-01-01 to 2022-09-30	-0.61	USD/shares	273
2021-07-01 to 2021-09-30	-0.17	USD/shares	92
2021-01-01 to 2021-09-30	2.15	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-0.17	USD/shares	92
2022-01-01 to 2022-09-30	-0.61	USD/shares	273
2021-07-01 to 2021-09-30	-0.17	USD/shares	92
2021-01-01 to 2021-09-30	2.14	USD/shares	273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	0	USD	92
2022-01-01 to 2022-09-30	0	USD	273
2021-07-01 to 2021-09-30	-294,829	USD	92
2021-01-01 to 2021-09-30	1,678,532	USD	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2022-09-30	1,159,657	USD
At 2021-12-31	242,757	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	4,827,072	USD	273
2021-01-01 to 2021-09-30	3,739,258	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-12,803,856	USD	92
2022-01-01 to 2022-09-30	-43,375,249	USD	273
2021-07-01 to 2021-09-30	-11,681,734	USD	92
2021-01-01 to 2021-09-30	150,562,757	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-09-30	140,498,139	USD
At 2021-12-31	190,479,129	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2022-09-30	1,033,066	USD
At 2021-12-31	7,127,046	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2022-09-30	275,448	USD
At 2021-12-31	164,092	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	12,814,958	USD	92
2022-01-01 to 2022-09-30	44,831,717	USD	273
2021-07-01 to 2021-09-30	11,681,734	USD	92
2021-01-01 to 2021-09-30	57,820,022	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	5,183,253	USD	92
2022-01-01 to 2022-09-30	19,062,192	USD	273
2021-07-01 to 2021-09-30	4,917,393	USD	92
2021-01-01 to 2021-09-30	28,849,969	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-09-30	70,466,885	shares
At 2021-12-31	70,364,912	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2022-09-30	60,187,439	USD
At 2021-12-31	189,728,285	USD
At 2021-09-30	201,779,567	USD
At 2020-12-31	72,033,930	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2022-09-30	-82,792	USD
At 2021-12-31	0	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2022-09-30	15,177,639	USD
At 2021-12-31	0	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2022-09-30	16,248,833	USD
At 2021-12-31	0	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2022-09-30	449,750	USD
At 2021-12-31	262,208	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2022-09-30	275,448	USD
At 2021-12-31	164,092	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2022-09-30	5,699,233	USD
At 2021-12-31	7,671,275	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2022-09-30	2,640,478	USD
At 2021-12-31	2,681,597	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-11,967,771	USD	92
2022-01-01 to 2022-09-30	-42,664,240	USD	273
2021-07-01 to 2021-09-30	-11,679,077	USD	92
2021-01-01 to 2021-09-30	150,513,164	USD	273

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-11,960,436	USD	92
2022-01-01 to 2022-09-30	-42,747,032	USD	273
2021-07-01 to 2021-09-30	-11,384,248	USD	92
2021-01-01 to 2021-09-30	148,834,632	USD	273

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-11,967,771	USD	92
2022-01-01 to 2022-09-30	-42,664,240	USD	273
2021-07-01 to 2021-09-30	-11,384,248	USD	92
2021-01-01 to 2021-09-30	144,989,259	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	7,631,705	USD	92
2022-01-01 to 2022-09-30	25,769,525	USD	273
2021-07-01 to 2021-09-30	6,764,341	USD	92
2021-01-01 to 2021-09-30	28,970,053	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	102,071	USD	92
2022-01-01 to 2022-09-30	187,541	USD	273
2021-07-01 to 2021-09-30	16,497	USD	92
2021-01-01 to 2021-09-30	52,974	USD	273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	327,525	USD	273
2021-01-01 to 2021-09-30	180,128	USD	273

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	53,348	USD	92
2022-01-01 to 2022-09-30	139,984	USD	273
2021-07-01 to 2021-09-30	35,681	USD	92
2021-01-01 to 2021-09-30	127,154	USD	273

Inspect the source

Entity: Ovid Therapeutics Inc. / CIK 0001636651
Captured: 2026-09-21T17:21:21.098Z
SEC response SHA-256: b4de1e66c6e8e0453b1f8d4fc2f1dafe6798859207cf5a42629d88fe4c5e512a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001636651.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))